SlideShare a Scribd company logo
Why should you
be concerned?
What ?
- High performance hematology

      Introduction
       Process
         Learning Points
800-beds;
       Opened 1997




          2007
2005
A Day @ Changi General Hospital
                       3161 staff
                     384 doctors
      800-beds       1451 nurses
    85% occupancy

       450-500
      Emergency
     attendances

      1000-1500
      Outpatient
     attendances

     10000-12000
      Laboratory
    investigations
Changi GH – Lab Medicine



Histopathology
                   Clinical Pathology
   X 4930 / 4931

                        Hematology           Transfusion

 Microbiology
     X 4935
                    Routine                   Microscopy
                               Immunoassay
                   Chemistry                  Urinalysis
Patient Load Increasing

                 Apr  Apr  Apr Apr Apr
                2006 2007 2008 2009 2010

Emergency
(attendances)   11239   12885   13398   13871   13344


CLINICS
(outpatients)
                25069   28325   30069   28665   28869
Increasing Clinical Pathology Workload


               350


               300


               250
Tests (,000)




               200


               150


               100


               50


                0
                     April 2007
                     April 2006   April 2007   April 2008   April 2009   April 2010
Workflow Challenges
      Batching, queuing
      STAT delays
      Review rates
      Transportation delays
      Reagent and instrument setup times
      Misplaced/misrouted samples
       (how many, time to locate)
      Instrument downtime
      Slide generation
10   Put science on your side.   ©2011 Abbott
                                 Company Confidential
Keeping Good Time
Tests           ER             Ward       Outpatients
 FBC      12 (45’ – 98%)   15 (45’ – 97%) 15 (45’ – 99%)
 INR      21 (45’ – 98%)   22 (45’ – 98%) 21 (45’ – 99%)
Renal     27 (45’ – 97%)   29 (45’ - 96%) 31 (45’ – 97%)
UrineA     9 (45’ – 99%)   10 (45’ – 99%) 12 (45’ – 99%)
 TnT      33 (45’ – 92%)   35 (45’ - 96%)
HbA1c                                     21 (45’ – 99%)
 Liver                                    33 (45’ – 96%)
Lipids                                    38 (45’ – 87%)
How ?

     Purpose
        Process
            People
 PURPOSE
●   Quality - high            ●   Results - fast & accurate
●   Cost - reasonable         ●   Information – useful &
                                  understandable
●   Delivery - ASAP
                              ●   Therapy – direction
●   Inconvenience - minimal
                              ●   Costs - not as important
• Technology - latest
• Risk - low
Rapid Results           STATs




=
Improved Patient Care
 PROCESS
 How?
   Pre-analytics
    Location
    Sample - Order Entry, Tubes, Logistics
   Analytics
    Sample – reception, processing
    Testing platforms, automation
    Right siting, right sizing
   Post-analytics
    Results – autovalidation / enquiry / printing
Divider Title 2
How ?
        1. Pre-Analytics
            - test request
            - sample collection
            - sample transport
Test
 Request
Individual Tests
     Panels
  Order Sets
Specimen
Collection
• Draw
• Sort
• Transport
Wards
                    Delivery time = 2 – 5 min




                         Clinics
        ICU


                          ER


              Lab
Divider Title 3
How ?
        2. Analytics
            - specimen processing
            - analyzers
            - lab layout
            - staffing
            ? TLA
+ HbA1c  20 / day          }
+ ESR  10 / day            } < 5% of 600 FBC/day
+ ESR + HbA1c  < 5 / day   }
Individual Circuit Breaker for each instrument
Look for clots BEFORE analysis




 + HbA1c  20 / day        }
 + ESR  10 / day          } < 5% of total FBC
 + ESR + HbA1c  5 / day   }
1. Throughput Is Adequate



   Workload: 300,000 FBC / year

              700-900/day

   600-780 day-time      100-120 after-hrs

   100-120/hr @ peak periods
2. Dynamic Range is Sufficient
3. Precision is Good
Within-day




Day-day

       Hb                                   WBC
                          RBC                                 PLT
 High   - cv 0.7%                      High   - cv 1.9%
 Normal - cv 0.9%   High   - cv 1.4%   Normal - cv 2.1%   High   - cv 3.1%
 Low    - cv 1.0%   Normal - cv 1.5%   Low    - cv 2.5%   Normal - cv 6.2%
                    Low    - cv 1.9%                      Low    - cv 6.6%
20
Low          Normal          High


WBC x 109/L


    Ruby (n = 175)   2.51 (3.9%)   8.07 (2.6%)    10.67 (2.5%)


Sapphire (n = 146)   2.62 (3.9)    8.19 (2.3%)    10.87 (2.6%)


Hb x g/dL            6.45 (2.2%)   14.02 (2.0%)   18.77 (2.1%)


Platelets x 109/L    85.9 (6.7%)   197.7 (6.1%)   397.9 (4.8%)
4. Reticulocytes
• Ruby reticulocyte method uses the thiazine dye New
  Methylene Blue N.
• Assay performed in the WOC channel.
• Sample preparation is performed manually. 20ul blood
  dispensed into a tube of Cell-Dyn reticulocyte reagent.
• Staining of reticulum is complete within 15 mins.
  Stained sample is aspirated in the open mode.
• Reticulocytes are reported (%R).
• Absolute reticulocyte count calculated if RBC
  concentration is entered.


               Less than 5 requests per day
> 6 sigma is world-class; < 3.4 defects / million episodes
Ruby IQC          RBC                    WBC               Hb             Platelet
Low                        4.2                 6.2                6.8                3.4
Normal                     4.6                 9.3                8.4                6.4
High                       5.4                 7.0                7.4                9.9


Sigma metric = (TEa – Bias) / cv                     > 4  -- 2 x 2 controls / day
                                                           -- one 2.5 s QC rule
           TEa (total error allowable)
Fluid        Cell type       Normal                Abnormal
CSF          Leucocytes      0-5/µL                >5/µL
Synovial     Leucocytes      <200/µL               >200/µL
             Erythrocytes    <2000/µL              >2000/µL
Pleural      Leucocytes      <1000/µL              >1000/µL
Pericardial Leucocytes       <1000/µL              > 1000/µL
Peritoneal   Leucocytes      <300/µL               >300/µL
             Erythrocytes    <100,000/µL           >100,000/µL
                     Strasinger, S.K. (1985) Urinalysis and body fluids,
                                              F.A. Davis, Philadelphia.
Extending

 Dynamic Range




Initial triage of body fluid cell counts vs. microscopy:

Synovial (<200 WBC/uL)        Pleural (<1000 WBC/uL)
Peritoneal (<300 WBC/uL)      Pericardial (<1000 WBC/uL)
? CSF (<5 WBC/uL – adults; <30 WBC/uL – neonates)
350 m2
A


A




    B    20 m

         B
Open Architecture . . . . .
Samples Received in a Day

                    250


                    200
Number of Samples




                    150
                                                                                 Public Holiday
                                                                                 Working Day
                    100


                    50


                      0
                          1
                              3
                                  5
                                      7
                                          9
                                              11
                                                   13
                                                        15
                                                             17
                                                                  19
                                                                       21
                                                                            23
                                               Time
Right Size
nights, weekends, public holidays
Divider Title 4
How ?
  3. Post-Analytics
      - critical lab values
      - autoverification
      Result Availability
      - local printing
      - intranet (lab)
      - electronic medical record   (EMR)
Hb (g/dL)                      <5        > 19.5             }
             WBC (x 109/L)                  <1        > 50               } < 5 /day
             Platelets (x 109/L)             < 20     > 800              }



                       Johns               Mayo              UCLA            MGH
                      Hopkins
Hb (g/dL)                    > 22   <6        > 20     < 6.5    > 18
WBC (x 109/L)      < 1.2     > 30   < 1.0     > 100    < 1.0    > 50   < 2.0   > 50
Platelets (x 109/L) < 10            < 40     > 1000 < 20       > 1000 < 50     > 999
Middleware – enables Auto-verification

     Success Criteria
     • Senior Leadership drive and goal
     • Repeated discussion of benefits
     • Evidence based justification
     • Taking small steps with proper checking




56
Critical Lab Values

                   5 / 19.5
                   1 / 50
                  20 / 800

Else Hold Back
                       Review 1:10
Continuing QA Validation
• Staff will regularly scroll through the data
  manager (10%) for potential discrepancy
  in results, note ID no., & sign document for
  review by senior staff.

• Senior QA Co-ordinator will review and file
  the documents.
No Hold Backs
  No Flags
Middleware – Impact of Autoverification




              Mean: 9 – 12 min
              90th centile: 21-28 min
              45 min TAT: 98.5 – 99.1%
Autoverification occurs in “middleware” server

 90% of results autoverified
 Faster turnaround time
 Increased capacity
Where Abbott Instrument Manager fits in

          Laboratory                               Hospital
          Information                            Information
            System                                 System



                                      Ethernet


                         Additional   Instrument
                        Instrument    ManagerTM
                        ManagerTM     Workstation
                        Workstation


 No limitations
  for added
 workstations…
                                         No limitations for
                                               added
                                         instrumentation…
Middleware – Instrument Manager
     Improve satisfaction and reduce costs by decreasing human
     errors and enabling quicker diagnosis
                                                       View all sample information
               Centralized Information                 Select a sample to view
                                                        patient and test data
       Quick, accurate diagnosis
       Improve consistency
       Reduce training time                                                               View patient
                                                                                            information


               Automated Tasks
       Centralized, intelligent verification
                                                                                           Manage
       Decrease human errors                                                               test results
       Standardize routine tasks                                                           (release, order
                                                                                            re-runs, etc.)


               Simplified Quality
       Increase quality control
       Share data with QC software                           Adaptable Workspaces
       Utilize moving averages                 Customize windows, color code and filter data as needed

63
Redundancy Features
                               Back-Up

 LIS Backup
  – Automatically print chartable reports
    to ER and ICU printers during
    downtime
  – Print LIS downtime labels
    automatically or on demand
  – Complete audit trail for full
    traceability
 Database backup
  – Enables active mirror of Instrument
    ManagerTM database
  – Real time, continuous data backup
  – Minimal downtime to failover
• Platelets > Hb > WBC
• Start by releasing ALL normal results + NO flags
                Then ALL no hold backs + NO flags
Differentials
• WBC & RBC morphology flags

• Rules to decide manual differential or slide review
Location   Apr2006      Jan2007        Feb2008    Mar2008

Wards         35’            29’            20’      18’
SICU        27-40’           36’            21’      19’
MICU        31-44’           32’            21’      19’
Clinics       25’            23’            20’      17’
ER          22-25’           22’            20’      18’

                     Mean: 9 – 12 min
                     90th centile: 21-28 min
                     45 min TAT: 98.5 – 99.1%
Results Availability

   Printing @ source      Web Query
                            - LIS
                            - EMR (electronic
                              medical record)
Bonus - Remote Diagnostics
      Maximum equipment uptime




                                                              Benefits
                                                     Fix it before it breaks
                                                     Faster response time
                                                     Engineers arrive with
                                                      the right parts
                          Monitor Instrument
                          Events and Alarms
                         Early error detection
                         Remote troubleshooting
                         Proactive on-site visit


74
Bonus - Reagent Management System (RMS)




75   Put science on your side.   ©2010 Abbott   Company
                                 Confidential
Workflow Challenges
 Batching, queuing  Process ASAR
 STAT delays  Pneumatic Tubes, ASAR
 Review rates  Autoverification
 Transportation delays  Pneumatic tubes
 Reagent and instrument setup times  Two
 Identical Analyzers, Always On, Reagent MxSystem
 Misplaced/misrouted samples  Right Siting
 Instrument downtime  Two Identical
 Analyzers, Always On, Abbott Link
 Slide generation  As needed
 77   Put science on your side.   ©2011 Abbott
                                  Company Confidential
 PROCESS
     Eliminate Waste
     - over-production
     - waiting
     - unnecessary transport
     - over/incorrect processing
     - defects
     - unused employee creativity

    Right Process - - > Right Results
    Continuous Process Flow
    No over-production (what he wants, when he wants,
     in the amount he wants)
    Level out workload
    Right quality first time
    Standardized task
    Visual control – no problems hidden
    Use reliable, tested technology
Start Small
Simplify
Streamline
Smoothing – flow, unevenness
Standardize
Skills
Staff
2. Focus on Processes
            Henry Ford Health Systems Labs
                 6 acute care hospitals
                   30 medical clinics
                        785 staff
                    11.1 million tests

                            Downtown Detroit Core Lab
                                      6.5 million tests

80   ©2011 Abbott
     Company Confidential
 PEOPLE
             Continuous Feedback
 In-house Coaching
    Lectures, brainstorming & discussion
    Select “best” champions - supervisors
    Morning Call

 External Dialog
    - doctors & nurses

 K.I.S.S.
    Keep it simply, simple
1
                            • Harness Technology

                            • Focus on Processes
          2

                            • Remember People
          3
82   ©2011 Abbott
              Chief (Clinical Effectiveness & Innovation)
     Company Confidential
Thank you for your time




 Put science on your side.       tarchoon@gmail.com
 18th May, Hong Kong

More Related Content

Similar to Prof aw tar [compatibility mode]

Automated sample preparation using the GERSTEL MPS Series and MAESTRO softwar...
Automated sample preparation using the GERSTEL MPS Series and MAESTRO softwar...Automated sample preparation using the GERSTEL MPS Series and MAESTRO softwar...
Automated sample preparation using the GERSTEL MPS Series and MAESTRO softwar...
GERSTEL
 
Peritoneal Dialysis And Secondary Renal Function
Peritoneal Dialysis And Secondary Renal FunctionPeritoneal Dialysis And Secondary Renal Function
Peritoneal Dialysis And Secondary Renal Function
Rodion Stolyar
 
Incorporating Peripherally Inserted Central Catheters (PICC) into hospital cl...
Incorporating Peripherally Inserted Central Catheters (PICC) into hospital cl...Incorporating Peripherally Inserted Central Catheters (PICC) into hospital cl...
Incorporating Peripherally Inserted Central Catheters (PICC) into hospital cl...
HTAi Bilbao 2012
 
Oligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake LaboratoriesOligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake Laboratories
Pine Lake Laboratories
 
POCT (Challenges in laboratory medicine)
POCT (Challenges in laboratory medicine)POCT (Challenges in laboratory medicine)
POCT (Challenges in laboratory medicine)
Nashwa Elsayed
 
eHealth Summit: "How a mathematical patient flow modelling study can eliminat...
eHealth Summit: "How a mathematical patient flow modelling study can eliminat...eHealth Summit: "How a mathematical patient flow modelling study can eliminat...
eHealth Summit: "How a mathematical patient flow modelling study can eliminat...
3GDR
 
Parallel Session 3.2 Innovations in Acute Flow and Capacity Management
Parallel Session 3.2 Innovations in Acute Flow and Capacity ManagementParallel Session 3.2 Innovations in Acute Flow and Capacity Management
Parallel Session 3.2 Innovations in Acute Flow and Capacity Management
NHSScotlandEvent
 
Work report_15_08_2016
Work report_15_08_2016Work report_15_08_2016
Work report_15_08_2016
Sonali Uttam
 
Hematology technology
Hematology technologyHematology technology
Hematology technology
manueldsx
 
AAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_RussellAAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_Russell
Lawrence Hwang
 
Specimen receiving
Specimen receivingSpecimen receiving
Specimen receiving
Mohamed Abukar
 
Dr. Darwin Reicks - Pre-screening of stud boars for low fertility: What are t...
Dr. Darwin Reicks - Pre-screening of stud boars for low fertility: What are t...Dr. Darwin Reicks - Pre-screening of stud boars for low fertility: What are t...
Dr. Darwin Reicks - Pre-screening of stud boars for low fertility: What are t...
John Blue
 
High-throughput and Automated Process Development for Accelerated Biotherapeu...
High-throughput and Automated Process Development for Accelerated Biotherapeu...High-throughput and Automated Process Development for Accelerated Biotherapeu...
High-throughput and Automated Process Development for Accelerated Biotherapeu...
KBI Biopharma
 
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
Quality Assistance s.a.
 
SMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.pptSMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.ppt
hirbogeremew2
 
Massachusetts General Hospital (PATA).pptx
Massachusetts General Hospital (PATA).pptxMassachusetts General Hospital (PATA).pptx
Massachusetts General Hospital (PATA).pptx
AhmadHamalawy1
 
So you want to do a: RNAseq experiment, Differential Gene Expression Analysis
So you want to do a: RNAseq experiment, Differential Gene Expression AnalysisSo you want to do a: RNAseq experiment, Differential Gene Expression Analysis
So you want to do a: RNAseq experiment, Differential Gene Expression Analysis
University of California, Davis
 
Transfusion tranmitted Infection- Testing platform& recommendations
Transfusion tranmitted Infection- Testing platform& recommendationsTransfusion tranmitted Infection- Testing platform& recommendations
Transfusion tranmitted Infection- Testing platform& recommendations
sanjay negi
 
SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...
SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...
SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...
SLAS (Society for Laboratory Automation and Screening)
 
Quality Control In Clinical Laboratory
Quality Control In Clinical LaboratoryQuality Control In Clinical Laboratory
Quality Control In Clinical Laboratory
Dr. Rajesh Bendre
 

Similar to Prof aw tar [compatibility mode] (20)

Automated sample preparation using the GERSTEL MPS Series and MAESTRO softwar...
Automated sample preparation using the GERSTEL MPS Series and MAESTRO softwar...Automated sample preparation using the GERSTEL MPS Series and MAESTRO softwar...
Automated sample preparation using the GERSTEL MPS Series and MAESTRO softwar...
 
Peritoneal Dialysis And Secondary Renal Function
Peritoneal Dialysis And Secondary Renal FunctionPeritoneal Dialysis And Secondary Renal Function
Peritoneal Dialysis And Secondary Renal Function
 
Incorporating Peripherally Inserted Central Catheters (PICC) into hospital cl...
Incorporating Peripherally Inserted Central Catheters (PICC) into hospital cl...Incorporating Peripherally Inserted Central Catheters (PICC) into hospital cl...
Incorporating Peripherally Inserted Central Catheters (PICC) into hospital cl...
 
Oligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake LaboratoriesOligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake Laboratories
 
POCT (Challenges in laboratory medicine)
POCT (Challenges in laboratory medicine)POCT (Challenges in laboratory medicine)
POCT (Challenges in laboratory medicine)
 
eHealth Summit: "How a mathematical patient flow modelling study can eliminat...
eHealth Summit: "How a mathematical patient flow modelling study can eliminat...eHealth Summit: "How a mathematical patient flow modelling study can eliminat...
eHealth Summit: "How a mathematical patient flow modelling study can eliminat...
 
Parallel Session 3.2 Innovations in Acute Flow and Capacity Management
Parallel Session 3.2 Innovations in Acute Flow and Capacity ManagementParallel Session 3.2 Innovations in Acute Flow and Capacity Management
Parallel Session 3.2 Innovations in Acute Flow and Capacity Management
 
Work report_15_08_2016
Work report_15_08_2016Work report_15_08_2016
Work report_15_08_2016
 
Hematology technology
Hematology technologyHematology technology
Hematology technology
 
AAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_RussellAAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_Russell
 
Specimen receiving
Specimen receivingSpecimen receiving
Specimen receiving
 
Dr. Darwin Reicks - Pre-screening of stud boars for low fertility: What are t...
Dr. Darwin Reicks - Pre-screening of stud boars for low fertility: What are t...Dr. Darwin Reicks - Pre-screening of stud boars for low fertility: What are t...
Dr. Darwin Reicks - Pre-screening of stud boars for low fertility: What are t...
 
High-throughput and Automated Process Development for Accelerated Biotherapeu...
High-throughput and Automated Process Development for Accelerated Biotherapeu...High-throughput and Automated Process Development for Accelerated Biotherapeu...
High-throughput and Automated Process Development for Accelerated Biotherapeu...
 
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
 
SMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.pptSMi_Presentation_v3_website_version.ppt
SMi_Presentation_v3_website_version.ppt
 
Massachusetts General Hospital (PATA).pptx
Massachusetts General Hospital (PATA).pptxMassachusetts General Hospital (PATA).pptx
Massachusetts General Hospital (PATA).pptx
 
So you want to do a: RNAseq experiment, Differential Gene Expression Analysis
So you want to do a: RNAseq experiment, Differential Gene Expression AnalysisSo you want to do a: RNAseq experiment, Differential Gene Expression Analysis
So you want to do a: RNAseq experiment, Differential Gene Expression Analysis
 
Transfusion tranmitted Infection- Testing platform& recommendations
Transfusion tranmitted Infection- Testing platform& recommendationsTransfusion tranmitted Infection- Testing platform& recommendations
Transfusion tranmitted Infection- Testing platform& recommendations
 
SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...
SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...
SLAS Screen Design and Assay Technology Special Interest Group SLAS2017 Prese...
 
Quality Control In Clinical Laboratory
Quality Control In Clinical LaboratoryQuality Control In Clinical Laboratory
Quality Control In Clinical Laboratory
 

More from andreei

Tibaru18
Tibaru18Tibaru18
Tibaru18
andreei
 
Tibaru17
Tibaru17Tibaru17
Tibaru17
andreei
 
Tibaru16
Tibaru16Tibaru16
Tibaru16andreei
 
Tibaru15
Tibaru15Tibaru15
Tibaru15andreei
 
Tibaru14
Tibaru14Tibaru14
Tibaru14
andreei
 
Tibaru13
Tibaru13Tibaru13
Tibaru13
andreei
 
Tibaru12
Tibaru12Tibaru12
Tibaru12
andreei
 
Tibaru11
Tibaru11Tibaru11
Tibaru11andreei
 
Tibaru9
Tibaru9Tibaru9
Tibaru9
andreei
 
Tibaru11
Tibaru11Tibaru11
Tibaru11
andreei
 
Tibaru10
Tibaru10Tibaru10
Tibaru10andreei
 
Tibaru7
Tibaru7Tibaru7
Tibaru7
andreei
 
Refhemabaru8
Refhemabaru8Refhemabaru8
Refhemabaru8
andreei
 
Refhemabaru7
Refhemabaru7Refhemabaru7
Refhemabaru7
andreei
 
Refhemabaru6
Refhemabaru6Refhemabaru6
Refhemabaru6
andreei
 
Refhemabaru5
Refhemabaru5Refhemabaru5
Refhemabaru5
andreei
 
12
1212
11
1111

More from andreei (20)

Tibaru18
Tibaru18Tibaru18
Tibaru18
 
Tibaru17
Tibaru17Tibaru17
Tibaru17
 
Tibaru16
Tibaru16Tibaru16
Tibaru16
 
Tibaru15
Tibaru15Tibaru15
Tibaru15
 
Tibaru14
Tibaru14Tibaru14
Tibaru14
 
Tibaru13
Tibaru13Tibaru13
Tibaru13
 
Tibaru12
Tibaru12Tibaru12
Tibaru12
 
Tibaru11
Tibaru11Tibaru11
Tibaru11
 
Tibaru9
Tibaru9Tibaru9
Tibaru9
 
Tibaru11
Tibaru11Tibaru11
Tibaru11
 
Tibaru10
Tibaru10Tibaru10
Tibaru10
 
Tibaru8
Tibaru8Tibaru8
Tibaru8
 
Tibaru7
Tibaru7Tibaru7
Tibaru7
 
Refhemabaru8
Refhemabaru8Refhemabaru8
Refhemabaru8
 
Refhemabaru7
Refhemabaru7Refhemabaru7
Refhemabaru7
 
Refhemabaru6
Refhemabaru6Refhemabaru6
Refhemabaru6
 
Refhemabaru5
Refhemabaru5Refhemabaru5
Refhemabaru5
 
12
1212
12
 
12
1212
12
 
11
1111
11
 

Recently uploaded

GlobalLogic Java Community Webinar #18 “How to Improve Web Application Perfor...
GlobalLogic Java Community Webinar #18 “How to Improve Web Application Perfor...GlobalLogic Java Community Webinar #18 “How to Improve Web Application Perfor...
GlobalLogic Java Community Webinar #18 “How to Improve Web Application Perfor...
GlobalLogic Ukraine
 
"Scaling RAG Applications to serve millions of users", Kevin Goedecke
"Scaling RAG Applications to serve millions of users",  Kevin Goedecke"Scaling RAG Applications to serve millions of users",  Kevin Goedecke
"Scaling RAG Applications to serve millions of users", Kevin Goedecke
Fwdays
 
JavaLand 2024: Application Development Green Masterplan
JavaLand 2024: Application Development Green MasterplanJavaLand 2024: Application Development Green Masterplan
JavaLand 2024: Application Development Green Masterplan
Miro Wengner
 
Y-Combinator seed pitch deck template PP
Y-Combinator seed pitch deck template PPY-Combinator seed pitch deck template PP
Y-Combinator seed pitch deck template PP
c5vrf27qcz
 
GNSS spoofing via SDR (Criptored Talks 2024)
GNSS spoofing via SDR (Criptored Talks 2024)GNSS spoofing via SDR (Criptored Talks 2024)
GNSS spoofing via SDR (Criptored Talks 2024)
Javier Junquera
 
What is an RPA CoE? Session 2 – CoE Roles
What is an RPA CoE?  Session 2 – CoE RolesWhat is an RPA CoE?  Session 2 – CoE Roles
What is an RPA CoE? Session 2 – CoE Roles
DianaGray10
 
"$10 thousand per minute of downtime: architecture, queues, streaming and fin...
"$10 thousand per minute of downtime: architecture, queues, streaming and fin..."$10 thousand per minute of downtime: architecture, queues, streaming and fin...
"$10 thousand per minute of downtime: architecture, queues, streaming and fin...
Fwdays
 
Mutation Testing for Task-Oriented Chatbots
Mutation Testing for Task-Oriented ChatbotsMutation Testing for Task-Oriented Chatbots
Mutation Testing for Task-Oriented Chatbots
Pablo Gómez Abajo
 
Day 2 - Intro to UiPath Studio Fundamentals
Day 2 - Intro to UiPath Studio FundamentalsDay 2 - Intro to UiPath Studio Fundamentals
Day 2 - Intro to UiPath Studio Fundamentals
UiPathCommunity
 
LF Energy Webinar: Carbon Data Specifications: Mechanisms to Improve Data Acc...
LF Energy Webinar: Carbon Data Specifications: Mechanisms to Improve Data Acc...LF Energy Webinar: Carbon Data Specifications: Mechanisms to Improve Data Acc...
LF Energy Webinar: Carbon Data Specifications: Mechanisms to Improve Data Acc...
DanBrown980551
 
From Natural Language to Structured Solr Queries using LLMs
From Natural Language to Structured Solr Queries using LLMsFrom Natural Language to Structured Solr Queries using LLMs
From Natural Language to Structured Solr Queries using LLMs
Sease
 
Apps Break Data
Apps Break DataApps Break Data
Apps Break Data
Ivo Velitchkov
 
What is an RPA CoE? Session 1 – CoE Vision
What is an RPA CoE?  Session 1 – CoE VisionWhat is an RPA CoE?  Session 1 – CoE Vision
What is an RPA CoE? Session 1 – CoE Vision
DianaGray10
 
"What does it really mean for your system to be available, or how to define w...
"What does it really mean for your system to be available, or how to define w..."What does it really mean for your system to be available, or how to define w...
"What does it really mean for your system to be available, or how to define w...
Fwdays
 
"Choosing proper type of scaling", Olena Syrota
"Choosing proper type of scaling", Olena Syrota"Choosing proper type of scaling", Olena Syrota
"Choosing proper type of scaling", Olena Syrota
Fwdays
 
"Frontline Battles with DDoS: Best practices and Lessons Learned", Igor Ivaniuk
"Frontline Battles with DDoS: Best practices and Lessons Learned",  Igor Ivaniuk"Frontline Battles with DDoS: Best practices and Lessons Learned",  Igor Ivaniuk
"Frontline Battles with DDoS: Best practices and Lessons Learned", Igor Ivaniuk
Fwdays
 
MySQL InnoDB Storage Engine: Deep Dive - Mydbops
MySQL InnoDB Storage Engine: Deep Dive - MydbopsMySQL InnoDB Storage Engine: Deep Dive - Mydbops
MySQL InnoDB Storage Engine: Deep Dive - Mydbops
Mydbops
 
Lee Barnes - Path to Becoming an Effective Test Automation Engineer.pdf
Lee Barnes - Path to Becoming an Effective Test Automation Engineer.pdfLee Barnes - Path to Becoming an Effective Test Automation Engineer.pdf
Lee Barnes - Path to Becoming an Effective Test Automation Engineer.pdf
leebarnesutopia
 
AppSec PNW: Android and iOS Application Security with MobSF
AppSec PNW: Android and iOS Application Security with MobSFAppSec PNW: Android and iOS Application Security with MobSF
AppSec PNW: Android and iOS Application Security with MobSF
Ajin Abraham
 
GraphRAG for LifeSciences Hands-On with the Clinical Knowledge Graph
GraphRAG for LifeSciences Hands-On with the Clinical Knowledge GraphGraphRAG for LifeSciences Hands-On with the Clinical Knowledge Graph
GraphRAG for LifeSciences Hands-On with the Clinical Knowledge Graph
Neo4j
 

Recently uploaded (20)

GlobalLogic Java Community Webinar #18 “How to Improve Web Application Perfor...
GlobalLogic Java Community Webinar #18 “How to Improve Web Application Perfor...GlobalLogic Java Community Webinar #18 “How to Improve Web Application Perfor...
GlobalLogic Java Community Webinar #18 “How to Improve Web Application Perfor...
 
"Scaling RAG Applications to serve millions of users", Kevin Goedecke
"Scaling RAG Applications to serve millions of users",  Kevin Goedecke"Scaling RAG Applications to serve millions of users",  Kevin Goedecke
"Scaling RAG Applications to serve millions of users", Kevin Goedecke
 
JavaLand 2024: Application Development Green Masterplan
JavaLand 2024: Application Development Green MasterplanJavaLand 2024: Application Development Green Masterplan
JavaLand 2024: Application Development Green Masterplan
 
Y-Combinator seed pitch deck template PP
Y-Combinator seed pitch deck template PPY-Combinator seed pitch deck template PP
Y-Combinator seed pitch deck template PP
 
GNSS spoofing via SDR (Criptored Talks 2024)
GNSS spoofing via SDR (Criptored Talks 2024)GNSS spoofing via SDR (Criptored Talks 2024)
GNSS spoofing via SDR (Criptored Talks 2024)
 
What is an RPA CoE? Session 2 – CoE Roles
What is an RPA CoE?  Session 2 – CoE RolesWhat is an RPA CoE?  Session 2 – CoE Roles
What is an RPA CoE? Session 2 – CoE Roles
 
"$10 thousand per minute of downtime: architecture, queues, streaming and fin...
"$10 thousand per minute of downtime: architecture, queues, streaming and fin..."$10 thousand per minute of downtime: architecture, queues, streaming and fin...
"$10 thousand per minute of downtime: architecture, queues, streaming and fin...
 
Mutation Testing for Task-Oriented Chatbots
Mutation Testing for Task-Oriented ChatbotsMutation Testing for Task-Oriented Chatbots
Mutation Testing for Task-Oriented Chatbots
 
Day 2 - Intro to UiPath Studio Fundamentals
Day 2 - Intro to UiPath Studio FundamentalsDay 2 - Intro to UiPath Studio Fundamentals
Day 2 - Intro to UiPath Studio Fundamentals
 
LF Energy Webinar: Carbon Data Specifications: Mechanisms to Improve Data Acc...
LF Energy Webinar: Carbon Data Specifications: Mechanisms to Improve Data Acc...LF Energy Webinar: Carbon Data Specifications: Mechanisms to Improve Data Acc...
LF Energy Webinar: Carbon Data Specifications: Mechanisms to Improve Data Acc...
 
From Natural Language to Structured Solr Queries using LLMs
From Natural Language to Structured Solr Queries using LLMsFrom Natural Language to Structured Solr Queries using LLMs
From Natural Language to Structured Solr Queries using LLMs
 
Apps Break Data
Apps Break DataApps Break Data
Apps Break Data
 
What is an RPA CoE? Session 1 – CoE Vision
What is an RPA CoE?  Session 1 – CoE VisionWhat is an RPA CoE?  Session 1 – CoE Vision
What is an RPA CoE? Session 1 – CoE Vision
 
"What does it really mean for your system to be available, or how to define w...
"What does it really mean for your system to be available, or how to define w..."What does it really mean for your system to be available, or how to define w...
"What does it really mean for your system to be available, or how to define w...
 
"Choosing proper type of scaling", Olena Syrota
"Choosing proper type of scaling", Olena Syrota"Choosing proper type of scaling", Olena Syrota
"Choosing proper type of scaling", Olena Syrota
 
"Frontline Battles with DDoS: Best practices and Lessons Learned", Igor Ivaniuk
"Frontline Battles with DDoS: Best practices and Lessons Learned",  Igor Ivaniuk"Frontline Battles with DDoS: Best practices and Lessons Learned",  Igor Ivaniuk
"Frontline Battles with DDoS: Best practices and Lessons Learned", Igor Ivaniuk
 
MySQL InnoDB Storage Engine: Deep Dive - Mydbops
MySQL InnoDB Storage Engine: Deep Dive - MydbopsMySQL InnoDB Storage Engine: Deep Dive - Mydbops
MySQL InnoDB Storage Engine: Deep Dive - Mydbops
 
Lee Barnes - Path to Becoming an Effective Test Automation Engineer.pdf
Lee Barnes - Path to Becoming an Effective Test Automation Engineer.pdfLee Barnes - Path to Becoming an Effective Test Automation Engineer.pdf
Lee Barnes - Path to Becoming an Effective Test Automation Engineer.pdf
 
AppSec PNW: Android and iOS Application Security with MobSF
AppSec PNW: Android and iOS Application Security with MobSFAppSec PNW: Android and iOS Application Security with MobSF
AppSec PNW: Android and iOS Application Security with MobSF
 
GraphRAG for LifeSciences Hands-On with the Clinical Knowledge Graph
GraphRAG for LifeSciences Hands-On with the Clinical Knowledge GraphGraphRAG for LifeSciences Hands-On with the Clinical Knowledge Graph
GraphRAG for LifeSciences Hands-On with the Clinical Knowledge Graph
 

Prof aw tar [compatibility mode]

  • 1.
  • 2. Why should you be concerned?
  • 3. What ? - High performance hematology  Introduction  Process  Learning Points
  • 4. 800-beds; Opened 1997 2007 2005
  • 5. A Day @ Changi General Hospital 3161 staff 384 doctors 800-beds 1451 nurses 85% occupancy 450-500 Emergency attendances 1000-1500 Outpatient attendances 10000-12000 Laboratory investigations
  • 6. Changi GH – Lab Medicine Histopathology Clinical Pathology X 4930 / 4931 Hematology Transfusion Microbiology X 4935 Routine Microscopy Immunoassay Chemistry Urinalysis
  • 7.
  • 8. Patient Load Increasing Apr Apr Apr Apr Apr 2006 2007 2008 2009 2010 Emergency (attendances) 11239 12885 13398 13871 13344 CLINICS (outpatients) 25069 28325 30069 28665 28869
  • 9. Increasing Clinical Pathology Workload 350 300 250 Tests (,000) 200 150 100 50 0 April 2007 April 2006 April 2007 April 2008 April 2009 April 2010
  • 10. Workflow Challenges  Batching, queuing  STAT delays  Review rates  Transportation delays  Reagent and instrument setup times  Misplaced/misrouted samples (how many, time to locate)  Instrument downtime  Slide generation 10 Put science on your side. ©2011 Abbott Company Confidential
  • 11. Keeping Good Time Tests ER Ward Outpatients FBC 12 (45’ – 98%) 15 (45’ – 97%) 15 (45’ – 99%) INR 21 (45’ – 98%) 22 (45’ – 98%) 21 (45’ – 99%) Renal 27 (45’ – 97%) 29 (45’ - 96%) 31 (45’ – 97%) UrineA 9 (45’ – 99%) 10 (45’ – 99%) 12 (45’ – 99%) TnT 33 (45’ – 92%) 35 (45’ - 96%) HbA1c 21 (45’ – 99%) Liver 33 (45’ – 96%) Lipids 38 (45’ – 87%)
  • 12. How ?  Purpose  Process  People
  • 14. Quality - high ● Results - fast & accurate ● Cost - reasonable ● Information – useful & understandable ● Delivery - ASAP ● Therapy – direction ● Inconvenience - minimal ● Costs - not as important • Technology - latest • Risk - low
  • 15. Rapid Results STATs = Improved Patient Care
  • 16.  PROCESS  How?  Pre-analytics Location Sample - Order Entry, Tubes, Logistics  Analytics Sample – reception, processing Testing platforms, automation Right siting, right sizing  Post-analytics Results – autovalidation / enquiry / printing
  • 17. Divider Title 2 How ? 1. Pre-Analytics - test request - sample collection - sample transport
  • 18. Test Request Individual Tests Panels Order Sets
  • 20.
  • 21. Wards Delivery time = 2 – 5 min Clinics ICU ER Lab
  • 22. Divider Title 3 How ? 2. Analytics - specimen processing - analyzers - lab layout - staffing ? TLA
  • 23.
  • 24. + HbA1c  20 / day } + ESR  10 / day } < 5% of 600 FBC/day + ESR + HbA1c  < 5 / day }
  • 25.
  • 26. Individual Circuit Breaker for each instrument
  • 27. Look for clots BEFORE analysis + HbA1c  20 / day } + ESR  10 / day } < 5% of total FBC + ESR + HbA1c  5 / day }
  • 28.
  • 29.
  • 30.
  • 31. 1. Throughput Is Adequate Workload: 300,000 FBC / year 700-900/day 600-780 day-time 100-120 after-hrs 100-120/hr @ peak periods
  • 32. 2. Dynamic Range is Sufficient
  • 33. 3. Precision is Good Within-day Day-day Hb WBC RBC PLT High - cv 0.7% High - cv 1.9% Normal - cv 0.9% High - cv 1.4% Normal - cv 2.1% High - cv 3.1% Low - cv 1.0% Normal - cv 1.5% Low - cv 2.5% Normal - cv 6.2% Low - cv 1.9% Low - cv 6.6%
  • 34. 20
  • 35. Low Normal High WBC x 109/L Ruby (n = 175) 2.51 (3.9%) 8.07 (2.6%) 10.67 (2.5%) Sapphire (n = 146) 2.62 (3.9) 8.19 (2.3%) 10.87 (2.6%) Hb x g/dL 6.45 (2.2%) 14.02 (2.0%) 18.77 (2.1%) Platelets x 109/L 85.9 (6.7%) 197.7 (6.1%) 397.9 (4.8%)
  • 36. 4. Reticulocytes • Ruby reticulocyte method uses the thiazine dye New Methylene Blue N. • Assay performed in the WOC channel. • Sample preparation is performed manually. 20ul blood dispensed into a tube of Cell-Dyn reticulocyte reagent. • Staining of reticulum is complete within 15 mins. Stained sample is aspirated in the open mode. • Reticulocytes are reported (%R). • Absolute reticulocyte count calculated if RBC concentration is entered. Less than 5 requests per day
  • 37. > 6 sigma is world-class; < 3.4 defects / million episodes Ruby IQC RBC WBC Hb Platelet Low 4.2 6.2 6.8 3.4 Normal 4.6 9.3 8.4 6.4 High 5.4 7.0 7.4 9.9 Sigma metric = (TEa – Bias) / cv > 4  -- 2 x 2 controls / day -- one 2.5 s QC rule TEa (total error allowable)
  • 38. Fluid Cell type Normal Abnormal CSF Leucocytes 0-5/µL >5/µL Synovial Leucocytes <200/µL >200/µL Erythrocytes <2000/µL >2000/µL Pleural Leucocytes <1000/µL >1000/µL Pericardial Leucocytes <1000/µL > 1000/µL Peritoneal Leucocytes <300/µL >300/µL Erythrocytes <100,000/µL >100,000/µL Strasinger, S.K. (1985) Urinalysis and body fluids, F.A. Davis, Philadelphia.
  • 39. Extending Dynamic Range Initial triage of body fluid cell counts vs. microscopy: Synovial (<200 WBC/uL) Pleural (<1000 WBC/uL) Peritoneal (<300 WBC/uL) Pericardial (<1000 WBC/uL) ? CSF (<5 WBC/uL – adults; <30 WBC/uL – neonates)
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47. 350 m2 A A B 20 m B
  • 48.
  • 50.
  • 51. Samples Received in a Day 250 200 Number of Samples 150 Public Holiday Working Day 100 50 0 1 3 5 7 9 11 13 15 17 19 21 23 Time
  • 52. Right Size nights, weekends, public holidays
  • 53. Divider Title 4 How ? 3. Post-Analytics - critical lab values - autoverification Result Availability - local printing - intranet (lab) - electronic medical record (EMR)
  • 54. Hb (g/dL) <5 > 19.5 } WBC (x 109/L) <1 > 50 } < 5 /day Platelets (x 109/L) < 20 > 800 } Johns Mayo UCLA MGH Hopkins Hb (g/dL) > 22 <6 > 20 < 6.5 > 18 WBC (x 109/L) < 1.2 > 30 < 1.0 > 100 < 1.0 > 50 < 2.0 > 50 Platelets (x 109/L) < 10 < 40 > 1000 < 20 > 1000 < 50 > 999
  • 55.
  • 56. Middleware – enables Auto-verification Success Criteria • Senior Leadership drive and goal • Repeated discussion of benefits • Evidence based justification • Taking small steps with proper checking 56
  • 57. Critical Lab Values 5 / 19.5 1 / 50 20 / 800 Else Hold Back Review 1:10
  • 58. Continuing QA Validation • Staff will regularly scroll through the data manager (10%) for potential discrepancy in results, note ID no., & sign document for review by senior staff. • Senior QA Co-ordinator will review and file the documents.
  • 59. No Hold Backs No Flags
  • 60. Middleware – Impact of Autoverification Mean: 9 – 12 min 90th centile: 21-28 min 45 min TAT: 98.5 – 99.1%
  • 61. Autoverification occurs in “middleware” server  90% of results autoverified  Faster turnaround time  Increased capacity
  • 62. Where Abbott Instrument Manager fits in Laboratory Hospital Information Information System System Ethernet Additional Instrument Instrument ManagerTM ManagerTM Workstation Workstation No limitations for added workstations… No limitations for added instrumentation…
  • 63. Middleware – Instrument Manager Improve satisfaction and reduce costs by decreasing human errors and enabling quicker diagnosis  View all sample information Centralized Information  Select a sample to view patient and test data  Quick, accurate diagnosis  Improve consistency  Reduce training time  View patient information Automated Tasks  Centralized, intelligent verification  Manage  Decrease human errors test results  Standardize routine tasks (release, order re-runs, etc.) Simplified Quality  Increase quality control  Share data with QC software Adaptable Workspaces  Utilize moving averages Customize windows, color code and filter data as needed 63
  • 64. Redundancy Features Back-Up  LIS Backup – Automatically print chartable reports to ER and ICU printers during downtime – Print LIS downtime labels automatically or on demand – Complete audit trail for full traceability  Database backup – Enables active mirror of Instrument ManagerTM database – Real time, continuous data backup – Minimal downtime to failover
  • 65. • Platelets > Hb > WBC • Start by releasing ALL normal results + NO flags Then ALL no hold backs + NO flags
  • 66. Differentials • WBC & RBC morphology flags • Rules to decide manual differential or slide review
  • 67.
  • 68.
  • 69. Location Apr2006 Jan2007 Feb2008 Mar2008 Wards 35’ 29’ 20’ 18’ SICU 27-40’ 36’ 21’ 19’ MICU 31-44’ 32’ 21’ 19’ Clinics 25’ 23’ 20’ 17’ ER 22-25’ 22’ 20’ 18’ Mean: 9 – 12 min 90th centile: 21-28 min 45 min TAT: 98.5 – 99.1%
  • 70. Results Availability  Printing @ source  Web Query - LIS - EMR (electronic medical record)
  • 71.
  • 72.
  • 73.
  • 74. Bonus - Remote Diagnostics  Maximum equipment uptime Benefits  Fix it before it breaks  Faster response time  Engineers arrive with the right parts Monitor Instrument Events and Alarms  Early error detection  Remote troubleshooting  Proactive on-site visit 74
  • 75. Bonus - Reagent Management System (RMS) 75 Put science on your side. ©2010 Abbott Company Confidential
  • 76.
  • 77. Workflow Challenges  Batching, queuing  Process ASAR  STAT delays  Pneumatic Tubes, ASAR  Review rates  Autoverification  Transportation delays  Pneumatic tubes  Reagent and instrument setup times  Two Identical Analyzers, Always On, Reagent MxSystem  Misplaced/misrouted samples  Right Siting  Instrument downtime  Two Identical Analyzers, Always On, Abbott Link  Slide generation  As needed 77 Put science on your side. ©2011 Abbott Company Confidential
  • 78.  PROCESS Eliminate Waste - over-production - waiting - unnecessary transport - over/incorrect processing - defects - unused employee creativity Right Process - - > Right Results Continuous Process Flow No over-production (what he wants, when he wants, in the amount he wants) Level out workload Right quality first time Standardized task Visual control – no problems hidden Use reliable, tested technology
  • 79. Start Small Simplify Streamline Smoothing – flow, unevenness Standardize Skills Staff
  • 80. 2. Focus on Processes Henry Ford Health Systems Labs 6 acute care hospitals 30 medical clinics 785 staff 11.1 million tests Downtown Detroit Core Lab 6.5 million tests 80 ©2011 Abbott Company Confidential
  • 81.  PEOPLE Continuous Feedback  In-house Coaching Lectures, brainstorming & discussion Select “best” champions - supervisors Morning Call  External Dialog - doctors & nurses  K.I.S.S. Keep it simply, simple
  • 82. 1 • Harness Technology • Focus on Processes 2 • Remember People 3 82 ©2011 Abbott Chief (Clinical Effectiveness & Innovation) Company Confidential
  • 83. Thank you for your time Put science on your side. tarchoon@gmail.com  18th May, Hong Kong